Evaluation of subchronic toxicity of SIM010603, a potent inhibitor of receptor tyrosine kinase, after 28-day repeated oral administration in SD rats and beagle dogs

Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association
Yu MaoGuocai Lu

Abstract

SIM010603, a promising multi-targeted receptor tyrosine kinase (RTK) inhibitor, is now being considered for evaluation in phase clinical trial. In this work, the subchronic toxicity of SIM010603 in SD rats and beagle dogs have been characterized. Rats and dogs received SIM010603 orally (0-20 and 0-10mg/kg/day, respectively) on a consecutive daily dosing schedule for 28 days following a 14 days recovery period. Sunitinib was used as a positive control. The No Observed Adverse Effect Level (NOAEL) of SIM010603 was 5mg/kg/day for rats, and undefined for dogs. The treatment resulted in unscheduled mortality in dogs receiving 10mg/kg of SIM010603 or Sunitinib. The adverse effects of SIM010603 on rats and dogs mainly included gastrointestinal toxicity, skeletal toxicity, myelosuppression, thymus atrophy, bronchopneumonia, cardiovascular dysfunction, and pancreatic toxicity. Similar observations have also been noted with this class of RTK signaling inhibitors and are consistent with pharmacologic perturbations of physiologic/angiogenic processes associated with the intended molecular targets. Most treatment-induced effects were reversible or showed ongoing recovery upon discontinuation of treatment. SIM010603 has shown comparable toxi...Continue Reading

References

Aug 16, 2002·The New England Journal of Medicine·George D DemetriHeikki Joensuu
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B C KuenenH M Pinedo
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Jun 5, 2003·Nature Medicine·Rakesh K Jain
Aug 2, 2003·The New England Journal of Medicine·James C YangSteven A Rosenberg
Jun 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonFairooz Kabbinavar
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Feb 4, 2005·Current Opinion in Gastroenterology·Yan Bi, John A Williams
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jul 25, 2006·Nature Medicine·Risto KerkeläThomas Force
Oct 13, 2006·Current Opinion in Gastroenterology·John A Williams
Dec 29, 2006·The New England Journal of Medicine·Charles E GeyerDavid Cameron
Mar 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Laura Q M Chow, S Gail Eckhardt
May 12, 2007·European Urology·Paul C M S Verhagen
Dec 18, 2007·Lancet·Tammy F ChuMing Hui Chen
May 9, 2008·The New England Journal of Medicine·Robert S Kerbel
Jul 4, 2008·Nature Reviews. Cancer·Lee M Ellis, Daniel J Hicklin
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 5, 2008·The New England Journal of Medicine·Giancarlo Spinzi, Silvia Paggi

❮ Previous
Next ❯

Citations

Oct 22, 2013·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Zhenna XiaGuocai Lu
Dec 6, 2016·International Journal of Environmental Research and Public Health·Xiaofang ZhangGuocai Lu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.